Phase Holographic Imaging PHI Valuation

Is PHI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PHI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PHI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHI?

Key metric: As PHI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PHI. This is calculated by dividing PHI's market cap by their current revenue.
What is PHI's PS Ratio?
PS Ratio	15.8x
Sales	SEK 10.69m
Market Cap	SEK 169.21m

PHI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.5x
Enterprise Value/EBITDA	-11x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does PHI's PS Ratio compare to its peers?

The above table shows the PS ratio for PHI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.9x
NANEXA Nanexa	3.4x	-79.8%	SEK 173.0m
ARCOMA Arcoma	0.9x	8.3%	SEK 146.4m
REDS Redsense Medical	4.2x	n/a	SEK 103.6m
SCIB SciBase Holding	3.2x	44.8%	SEK 86.5m
PHI Phase Holographic Imaging PHI	15.8x	n/a	SEK 169.2m

Price-To-Sales vs Peers: PHI is expensive based on its Price-To-Sales Ratio (15.8x) compared to the peer average (11.3x).

Price to Sales Ratio vs Industry

How does PHI's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
ARJO B Arjo	0.8x	3.7%	US$816.55m
CARE Careium	0.8x	10.2%	US$63.74m
BOUL Boule Diagnostics	0.5x	6.4%	US$25.89m
ARCOMA Arcoma	0.9x	8.3%	US$13.22m

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PHI is expensive based on its Price-To-Sales Ratio (15.8x) compared to the Swedish Medical Equipment industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is PHI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	15.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHI's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Arcoma

SEK 146.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 11.10

2.8%

49.0%

Mentice

SEK 560.0m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 21.90

2.8%

-46.6%

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.19

3.5%

-45.9%